NASDAQ: BIOA
BioAge Labs Inc.
Healthcare · Biotechnology
Pre-market: $10.94(-2.93%) · as of 4:00 AM ET
Market Cap
$424.31M
52w High
$25.96
52w Low
$4.25
P/E
-4.74
Volume
821.49K
Outstanding Shares
37.65M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 160.28% over the last year. Revenue grew 168.06% over the trailing twelve months. Operating margin moved from -2,364.2% to -1,026.28%. Free cash flow declined 92.33% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
Operating margin is at -1,026.28%. Revenue grew 168.06% — this thesis depends on that trajectory holding. Despite the price move, free cash flow fell 92.33%, which is worth watching as a leading indicator of future pressure. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
4
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 5, 2026
Q4 FY26 · EPS est -$0.64 · Revenue est $1.46M
View